ZNTL Stock Summary and Trading Ideas (Zentalis Pharmaceuticals | NASDAQ:ZNTL)

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Zentalis Pharmaceuticals trades on the NASDAQ stock market under the symbol ZNTL.

As of February 17, 2026, ZNTL stock price declined to $2.36 with 179,595 million shares trading.

ZNTL has a beta of 3.00, meaning it tends to be more sensitive to market movements. ZNTL has a correlation of 0.15 to the broad based SPY ETF.

ZNTL has a market cap of $170.51 million. This is considered a Micro Cap stock.

In the last 3 years, ZNTL traded as high as $31.46 and as low as $1.01.

The top ETF exchange traded funds that ZNTL belongs to (by Net Assets): VTI, VXF, FESM, PRFZ, IWC.

ZNTL has underperformed the market in the last year with a price return of -2.9% while the SPY ETF gained +13.1%. However, in the short term, ZNTL had mixed performance relative to the market. It has outperformed in the last 3 months, returning +78.8% vs +1.9% return in SPY. But in the last 2 weeks, ZNTL shares have been beat by the market, returning -2.9% compared to an SPY return of -1.4%.

ZNTL support price is $2.22 and resistance is $2.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZNTL shares will trade within this expected range on the day.